IMFINZI® (durvalumab) plus LYNPARZA® (olaparib) re

WILMINGTON, Del.--(BUSINESS WIRE)--Oct 21, 2023--

Related Keywords

Texas , United States , Japan , Madrid , Spain , Cambridge , Cambridgeshire , United Kingdom , China , Ottawa , Ontario , Canada , American , America , Canadian , Chelsea Ford , Brendan Mcevoy , Susan Galbraith , Shannonn Westin , European Society For Medical Oncology , Merck Co Inc , Canadian Agency For Drugs , Astrazeneca , Technologies In Health , University Of Texas Md Anderson Cancer Center , World Cancer Research Fund International , Us Electronic Health Records , American Cancer Society , Medical Oncology , Control Arm , Gynecologic Oncology , Reproductive Medicine , Cancer Center , Executive Vice President , Fatal Immune Mediated Adverse , Mediated Nephritis , Stevens Johnson Syndrome , Full Prescribing Information , Medication Guide , Acute Myeloid Leukemia , Fetal Toxicity , First Line Maintenance , Advanced Ovarian , First Line Maintenance Advanced Ovarian Cancer , Recurrent Ovarian , Adjuvant Treatment , High Risk Early Breast , Negative Metastatic Breast , Metastatic Pancreatic , Metastatic Castration Resistant Prostate , Metastatic Castration Resistant Prostate Cancer , Positive Advanced Ovarian Cancer , Line Maintenance , Prescribing Information , South America , Rare Diseases , Endometrial Cancer , Risk Factors , Accessed October , Practice Guidelines , Cancer Research Fund , Estimated Numbers , Endometrial Cancer Carboplatin Paclitaxel Regimen , Serous Carcinoma , Key Advances , Novel Treatment , Int Gynecol , Low Grade Stage Endometrial Cancer With , World Outcomes , Advanced Endometrial Cancer , Retrospective Cohort Study , Prospective Molecular Characterization , Advanced Endometrial , Clin Cancer , Repair Deficiency Tumour Testing , Patients With Colorectal Cancer , Muse Report , Canadian Agency , Business Wire , National Business ,